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ACMD 
Advisory Council on the Misuse of Drugs 
Chair: Professor Les Iversen 
Secretary: Will Reynolds  
3rd Floor Seacole Building  
2 Marsham Street  
London  
SW1P 4DF  
020 7035 0454 
Email: ACMD@homeoffice.gsi.gov.uk  
Dr Mark Prunty 
Wellington House, 
133-155 Waterloo Road, 
London 
SE1 8UG 
         21st December 2011  
 
Dear Dr Prunty,  
 
Re: Consideration of the use of foil as an intervention, to reduce the harms of 
heroin and cocaine. 
 
Thank you for your letter of 12th August 2011. The ACMD are pleased to enclose 
further advice, as requested, about the risks of physical harms from smoking heroin 
and cocaine.  
 
The three questions that you raise are:  
 
1) The effects of heroin and crack cocaine on the lungs (following inhalation) 
2) The thermal effects of smoking from foil on lung health  
3) The risks of infections from smoking heroin (e.g. non-injecting routes of 
Hepatitis C transmission). 
 
The ACMD is mindful that in consideration of whether foil should be provided as 
legal paraphernalia a key issue is weighing the risk of physical harm from smoking 
against the risk of injecting.  
 
In objectively considering the questions you raise, the ACMD has obtained evidence 
from peer review journals, reports and further discussion with experts.  
 
The findings of the attached report are supportive of those in the ACMD report 
Consideration of the use of foil as an intervention, to reduce the harms of injecting 
heroin (available at: http://www.homeoffice.gov.uk/publications/agencies-public-
bodies/acmd1/foil-report). The ACMD believe that foil, as an intervention, can 
support an individual‟s treatment journey towards recovery. In addressing these 
further questions, the ACMD consider that there is a strong case that foil is 
exempted under Section 9A of the Misuse of Drugs Act 1971. 
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The ACMD would wish to make clear that, in its consideration, the physical harms of 
smoking are significantly less than those associated with injecting. These were 
summarised recently by the Department of Health publication “A summary of the 
health harms of drugs”1 which highlighted that smoking, compared with injecting, 
presents significantly reduced risks associated with: 
 blood borne viruses, 
 systemic infections; 
 soft tissue and venous damage; and, 
 overdose.   
 
The questions you pose are pertinent since, should foil be provided, it is important to 
be aware of, and put in place measures to mitigate against, the different risk factors 
with smoking.  
 
Therefore, the ACMD suggest that, if services provide foil they should: 
 encourage people who inject drugs to switch to less harmful methods of drug 
use e.g. smoking; 
 discuss treatment options and signpost to other providers if service users 
want to address their drug use; 
 provide health promotion advice, for example, blood borne virus screening, 
vaccination and sexual health advice;  
 ensure staff are aware of the respiratory complications of smoking from foil, 
can provide advice on this and signpost to services for further screening if 
required; and, 
 ensure staff have the appropriate training to deliver these interventions and 
support service users in making changes that supports their recovery. 
 
The ACMD advice on foil is consistent with public health guidance 18 issued by the 
National Institute for Health and Clinical Evidence (NICE), „Needle and syringe 
programmes: providing people who inject drugs with injecting equipment‟ (February 
2009).  The ACMD considers that recommendation 4 („equipment and advice‟) is 
particularly relevant as it recommends that people who inject drugs should be 
encouraged to “switch to other methods of drug use” - the provision of foil will 
support this recommendation. 
 
The ACMD has drafted „best practice guidance around mitigating the health risks of 
smoking heroin/crack cocaine‟ that may assist in delivering foil as an intervention – 
see Annex 1. Should Ministers consider accepting the ACMD‟s advice it would 
welcome discussion in developing this document.   
 
Yours sincerely,  
 
Professor Les Iversen FRS 
 
Cc: Anne Milton 
      Lord Henley 
                                            
1
 Department of Health.  A summary of the health harms of drugs.  August 2011. 
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Report into the physical effects of smoking heroin/crack cocaine 
and the risks of infections.  
 
The ACMD provides the following short report in response to questions (in bold as 
headers) concerned with the risks of physical harms from smoking heroin/crack 
cocaine. 
 
1. The effects of heroin and crack on the lungs (following inhalation) 
2. The thermal effects of smoking from foil on lung health  
 
Tashkin[1] has summarised the pulmonary harms caused by smoking heroin and 
other illicit drugs. 
  
Toxic leukoencephalopathy (structural alterations of neuronal white matter in 
cerebellum and/or cerebral cortex) is a rare and potentially lethal adverse effect 
associated with heroin vapour inhalation [2], although it has also been seen after 
administration through other routes[3]. It is estimated that 25% of cases result in 
fatality. It is uncertain whether leukoencephalopathy results from use of „adulterated‟ 
or „contaminated‟ street heroin, or is a toxicological risk of pure heroin.   
 
Heroin-induced bronchoconstriction can be particularly severe in patients with 
already recognized asthma[4]. Possible mechanisms leading to heroin-induced 
bronchospasm include local airway irritation from the heroin fumes, including 
impurities in the inhaled mixture, and opiate stimulated histamine release[4] In a cross 
sectional study of 100 community methadone patients, a significant association 
between heroin-smoking, FEV1 (exhaled volume) and prevalence of dyspnoea 
(shortness of breath) was found[5]. Twenty per cent of subjects experienced 
dyspnoea while „walking at a normal pace with someone of their own age‟ 
Tobacco smoking is considered to worsen pulmonary outcomes, and is an important 
confound in this type of research. Smoking prevalence is greater in heroin users than 
in the general population[6] and furthermore, some research has suggested that 
cigarette smoking is greater in heroin smokers than injectors[6]. 
 
Smoking cocaine also causes bronchoconstriction and long term use can lead to 
significant damage to the lungs, resulting in a range of chronic diseases. A US study 
reported that up to half of cocaine users presenting to hospital with respiratory 
complaints were found to have abnormal chest radiographs[7] Acute use of smoked 
crack cocaine can also cause intense vasoconstriction, causing symptoms of severe 
chest pain, difficulty breathing and fever, a syndrome known as “crack lung” which 
may also become a chronic condition with prolonged drug use[8]. 
 
Thermal airway injury may be secondary to drug use, leading to tracheal stenosis; it 
may result from either (a) inhalation injury from chemical by products transported in 
the smoke, or (b) intratracheal combustion of highly inflammable solvents used in the 
production process[9]. Inhalation of hot drug vapour may in itself be associated with 
thermal damage to the lungs, but no studies were identified which had examined this 
in detail. 
 
It should be noted that IV use of heroin is also a risk factor associated with 
pulmonary infections, including[10]: 
 More cases of community-acquired pneumonia; 
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 Lung abscess formation; 
 Septic emboli with or without endocarditis; 
 M. tuberculosis and bronchitis; 
 Bronchiectasis 
 Pleural and mediastinal infection 
 
 
3. The risks of infections from smoking heroin or cocaine (e.g. non-
injecting routes of Hepatitis C transmission). 
 
The ACMD Report on Hepatitis C[11] reported that 80% of Hepatitis C infections were 
associated with intravenous drug use, and  HPA‟s Shooting Up series of reports (last 
published in November 2011)[12] presents data from a sample of IDUs drawn from 
needle exchange services. In 2010, around one-half of injecting drug users were 
infected with Hepatitis C, one-sixth with Hepatitis B, and about one-third reported a 
symptom of a bacterial infection (such as a sore or abscess) at an injecting site in 
the past year. Transmission of HIV through drug use is low in the UK (approximately 
1.1% of IDUs in England, Wales and Northern Ireland in 2010), but this has 
increased from 0.7% in the last decade. 
 
Scheinmann and colleagues[13] conducted a systematic review of the evidence on 
the prevalence of Hepatitis C Virus (HCV) in non-injecting drug users who reported 
use of heroin, cocaine, crack or methylamphetamine (although there was some 
(small) concern raised by the authors that the studies (inadvertently) included IDUs) 
for which they concluded that HCV prevalence was higher than in non-drug using 
populations. Risk factors of HCV included sharing a crack pipe (material not 
mentioned) or a rolled bank note for heroin use. One of the studies reviewed 
reported that „ever sharing‟ „non-injected heroin implements‟ was a significant risk 
factor for HCV. However, no specific data on risks from smoking heroin on foil was 
presented.  
 
A nationally representative study conducted in Luxembourg found that 
seroprevalence of a range of blood borne virus in treatment service clients and 
prisoners was less in non-injecting drugs users than injectors[14]. For example, HIV 
prevalence was 19.1% (non-IDU) vs 81.3% (IDU); and HCV 8.9% vs 29.1%. A 
similar study of Italian heroin users estimated that HCV seroprevalence was 11 times 
less in non-IDU than IDU[15].In such surveys it is always possible that the “non-IDU” 
group contains some mixed non-IDU/IDU subjects. 
 
A cross-sectional study of young adults in an impoverished neighbourhood in New 
York City investigated the relationships between drug use and prevalence of sexually 
transmissible infections[18]. The research team concluded that HCV infection was 
concentrated among „drug injectors‟ and the calculated odds ratios for men and 
women were 40.6 (95% CI 8.7-292) and 149 (95% CI 31.0-999+) respectively.  
There were also increased risks of contracting HIV, HSV-2 and hepatitis B for both 
groups.  The researchers note wide CI due to the limited numbers of infected 
individuals but concluded that some infections, notably HIV, HCV and, for women, 
syphilis, were concentrated among IDUs. 
 
Another study of New York heroin users (where heroin inhalation over foil has 
historically been high) found that „never-injectors‟ infected with HIV and HBV were 
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mostly infected through sexual transmission, whereas injectors appear to have 
become infected with HIV and HCV mainly though injecting risk and with HBV 
through both injecting and sexual risk[16]. 
 
A study conducted in 1990 in Amsterdam investigated the prevalence, incidence and 
risk factors of HCV infection among drug users[17]. The researchers reported that 
IDU‟s had a seroprevalence of 74% versus 10% in non-IDU‟s. Risk factors reported 
as being independently associated with HCV antibody seropositivity were history and 
duration of intravenous drug use and frequency of injections. Daily smoking of heroin 
in the previous 6 months was independently associated with the absence of HCV 
antibodies.  
 
There is evidence for an independent association of crack cocaine use and smear 
positive (active) tuberculosis (TB). In a case control study in London 86% of crack 
users tested smear positive for TB compared with 36% in non-drug users[19] 
 
Whilst the presence of potential confounds makes the assessment of risk of viral or 
bacterial infection in users of foil is difficult, several studies, such as those cited 
above, have shown markedly lower rates of infection in non-IDU heroin users.  
However, rates of hepatitis C infection are still higher in non-injecting drug users than 
in the general population[20]. This could be due to a number of factors: – 
contamination of non-injecting drug groups with occasional injectors; sexual 
transmission[16]; contamination of the drug sample; or contamination of the smoking 
equipment with hepatitis C virus[21]. Hepatitis C infection is more common in older 
non-injecting users, those with tattoos, and crack cocaine users who share inhalation 
implements[22].  
 
An outbreak of severe soft tissue infection among heroin injecting drug users was 
reported in Glasgow, Scotland in 2002 [22]. The most frequently isolated pathogen 
was Clostridium novyi type A, and findings pointed to contaminated heroin that was 
injected as the source of infection[23]. Other pathogenic clostridia such as Clostridium 
histolyticum, Clostridium sordellii, Clostridium perfringens, Clostridium septicum and 
Clostridium bifermentans have also been reported following intra muscular injecting 
practice[24].  
 
 There are no reliable statistics comparing rates of viral or bacterial infection in crack 
cocaine users employing the traditional smoking equipment as opposed to foil. 
However, since the boiling point of cocaine base is 187-188˚C, and heroin is 272-
274˚C, (Merck Index) and the temperature of foil when heated can rapidly rise to as 
high as 600˚C[25] it would seem very unlikely that viral infection could occur by this 
route, even if the sample of cocaine or heroin was contaminated. 
 
A review of more than fifteen years of Dutch experience in switching IDUs to foil [26] 
reported uniformly positive public health outcomes and an almost complete switch 
from injecting to use of foil. However, respiratory complaints are regularly seen and 
these can be severe, emphasising the need for public health warnings to foil users. 
 
If foil were legally available, this would be in accordance with the recommendation in 
NICE (2009) public health guidance 18[27]: 
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“Provide other injecting equipment associated with illicit drug use and encourage 
people who inject drugs to switch to other methods of drug use. (At the time of 
publication, legally permitted equipment included filters, mixing containers and sterile 
water.)” 
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Annex 1. Best practice guidance around mitigating the health risks of smoking 
heroin/crack cocaine. 
 
It is incumbent on any practitioner to offer alternatives to risk taking behaviour at any 
point on an individuals‟ treatment journey. Although this applies to all forms of drug 
use and routes of administration, there are significant harms associated with 
intravenous administration of drug, particularly heroin and crack cocaine, mean that 
proactive interventions should engage and support around route transitions away 
from injecting drug use.  
 
Promotion of smoking and foil distribution should be used to address the following 
needs of three groups;   
a) encourage heroin and cocaine smokers into early and regular contact with 
services to prevent initiation into injecting;  
b) raise awareness of foil as an intervention amongst those individuals who may 
be „foil naïve‟; and,  
c) provision of foil as an engagement tool with people still actively injecting.  
 
Promoting smoking and thereby reducing harm by providing foil 
The promotion of smoking drugs as an alternative to injection by providing foil is 
considered to have the following objectives: 
 To promote transition prevention - dissuading smokers/chasers moving to 
injecting as route of drug transmission; 
 To promote reverse transition - supporting switch from injecting to smoking as 
a route of drug transmission; and, 
 To promote lower levels of dependence, reduced blood borne virus and 
bacterial transmission and reduced overdose risk. 
Educating the benefits of smoking over injecting should be central to transition and 
reverse transition interventions. Transition intervention require practitioners to 
highlight that the following risks are largely eliminated when drugs are smoked: 
 • Contracting Hep B, Hep C and HIV through injecting 
 • Abscesses, Cellulitis or Phlebitis 
 • Thrombosis (Vein Collapse) 
 • Deep Vein Thrombosis (DVT) and pulmonary Embolism (PE) 
 • Gangrene 
 • Fungal Infections 
 • Septicaemia 
 • Endocarditis 
 • Ulcers or Arterial Damage 
 • Seriously reduces the risk of overdose when compared to injecting. 
 
Smoking may be unattractive to injectors who may have previous negative 
experiences of chasing and such experiences need to be acknowledged and 
understood while remaining positive about chasing as an option at times when 
injecting becomes less feasible or attractive to the individual. 
 
It is important recognise that for many injectors a move away from injecting can be a 
cause for anxiety about reduced drug impact and effectiveness, onset of withdrawal 
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and the need for increased income to support what can be seen as a less effective 
route of administration. 
 
However all people who inject drugs (PWID) can benefit from switching to smoking 
their drugs and there are particular situations and presentations where targeted 
transition interventions should be offered and where promotion of a move to smoking 
would be more attractive: 
 Restricted venous access  
 Consideration or recent move to femoral or similarly dangerous injecting site 
 When experiencing significant harms associated with femoral of other deep 
vein injecting 
 On release from prison or after recent detoxification 
 New initiates to injecting where tolerance levels are typically low 
Smoking as step toward other recovery oriented drug treatment interventions  
Basic harm reduction is the first step on the hierarchy of goals which includes where 
relevant access to substitute prescribing, specialist psychosocial interventions and 
abstinence through detoxification   
 
Hierarchy of Goals   
  • Reduce sharing of injecting equipment 
  • Reduce injecting 
  • Reduce use of street drugs 
  • Reduce use of prescribed drugs 
  • Increase abstinence. 
 
(ACMD, AIDS and Drug Misuse 1998) 
Interim report of the Recovery Oriented Drug Treatment Review Group, Strang 2011 
 
Advice in promoting the transition from injecting to smoking 
The following is a list of basic advice (that should be augmented with services) in 
promoting the transition from injecting to smoking:  
 
 Encourage the use of crack pipes and lip balm/Vaseline to prevent cracked 
lips. 
 
 Offer advice on what to look out for in terms of symptoms and signs of a chest 
infection so that early treatment can be sourced prior to the development of a 
serious infection/pneumonia.  
 
 Offer specific advice to individuals with pre existing respiratory conditions 
such as Asthma and Chronic Obstructive Pulmonary Disease (COPD) - 
encouraging and supporting people to have regular asthma checks with their 
GP, to understand how to step up their  inhalers, (relievers and preventers), in 
response to worsening symptoms such as shortness of breath and wheeze. 
Encourage such patients to be aware of how to check their lung function using 
their home peak flow meter and to know when their lung function is 
deteriorating and to use this as a means of placing some controls on their 
smoking.  
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 Substance misuse workers and well being nurses working in substance 
misuse services should be aware of those individuals with associated 
respiratory co morbidity through careful assessment and ensure that they 
have active respiratory self management plans in place and are regularly 
accessing COPD/asthma clinics in primary care.  
 
 Be aware of the strong link between opiate and crack  smokers and nicotine 
smoking. Encouraging individuals to consider stopping smoking nicotine 
through access stop smoking advisory services or their GP and introducing 
them to range of interventions on offer to assist people to quit including 
nicotine patches, gums etc and some pharmacological adjuncts proven to 
reduce cravings.  
 
Summary  
Services should provide a range of responses that support people away from 
injecting which can include OST. 
 
We should be mindful / aware of the trigger points / red flags on a patient‟s journey 
where engaging with the service user to offer alternatives could instigate a change in 
behaviour. 
  
Harm reduction providers should be supplying foil as part of an holistic range of harm 
reduction interventions which support a hierarchy of needs toward individualised 
recovery goals and general health and well being.  
 
Services must provide an environment where service users have the opportunity to 
be able to speak confidentially and be supported by workers who are empathic non 
judgemental and be managed with privacy and dignity. 
  
Services providing foil should ensure they are operated by individuals with the 
competencies to be able to effectively assess someone‟s risk taking behaviour 
including injecting risk. They should be able to articulate the risks vs. benefits of 
offering safer alternatives such as smoking and chasing. 
 
 
